Zydus Lifesciences reports strong Q2, eyes ₹5,000 crore fundraise

Zydus Lifesciences Limited has reported a 16.9% increase in consolidated total income from operations to ₹61,232 million for Q2 FY26, with net profit after tax up 38.1% to ₹12,586 million compared to Q2 FY25. For the half year ended September 30, 2025, consolidated total income from operations grew 10.9% to ₹126,969 million, and net profit surged 16.9% to ₹27,254 million. The company's US formulations business delivered strong double-digit year-over-year growth, and its India branded formulations outpaced IPM growth by 9% year-over-year.

The board of directors also approved a proposal to raise funds up to ₹5,000 crore through the issuance of eligible securities. This fundraise may occur via qualified institutions placement(s), rights issue, preferential allotment, private placement(s), or a combination of these methods, subject to shareholder and regulatory approvals. The board also approved a postal ballot notice to seek member approval for this matter.

The board meeting commenced at 11:00 a.m. and concluded at 1:00 p.m. on November 6, 2025. The company's unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were reviewed by the audit committee and approved by the board. The trading window for Zydus Lifesciences securities will remain closed until November 8, 2025, reopening on November 10, 2025.